Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Retrograde Approach to Chronic Total Occlusions: Techniques and Outcomes According to the PROGRESS-CTO Registry

The retrograde approach for recanalizing chronic total occlusions (CTO) has undergone significant evolution since its introduction in 1990, improving both in terms of techniques and specialized materials. The increased skill applied to this strategy has resulted in increased success rates for the treatment of CTO in sites with an adequate volume of procedures.

Abordaje retrógrado en oclusiones totales crónicas: técnicas y eventos según el registro PROGRESS-CTO

Given the inherent complexity of the retrograde approach, it has historically been associated with lower success rates and a higher incidence of complications. This study sought to assess the results of the retrograde approach through a multicenter CTO registry (PROGRESS-CTO).

Researchers conducted a prospective registry analysis in high-volume centers distributed across 44 locations, including the United States, Canada, Egypt, Greece, Russia, and Turkey, where the retrograde approach was applied as the primary or secondary approach. The analyzed parameters included quality of the distal vessel, calcification presence and degree, and proximal tortuosity.

The main indicators assessed were technical success, defined as revascularization with residual stenosis ≤30%, and procedural success, defined as technical success without in-hospital adverse events (death, myocardial infarction, recurrent symptoms requiring new revascularization, bypass surgery, tamponade, or stroke).

Read also: Outcomes of the Use of Drug Coated Balloons in the Treatment of De Novo Coronary Lesions.

Out of a total of 11,808 registered CTO percutaneous coronary interventions (PCI), there were 4058 attempts at a retrograde approach. The average patient age was 64.6±10.4 years, and 84% of patients were men. There was a high prevalence of comorbidities: 89.9% of subjects had arterial hypertension, 89.1% had dyslipidemia, 69.3% had undergone prior PCI, and 42.5% had undergone prior myocardial revascularization surgery (MRS).

The right coronary artery was the most frequently treated vessel (67.4%), followed by the anterior descending artery (16.2%). The average J-CTO was 3.1±1.1, and the PROGRESS-CTO was 1.3±0.9. In 22.3% of cases, CTO treatment was attempted at least once. Additionally, 59.9% of subjects had moderate/severe calcification, 40.8% had moderate/severe proximal tortuosity, and 56.6% had proximal cap ambiguity. The average occlusion length was 4.1±24.5 mm, and most aptients had Werner class 1 collaterals (55.8%).

The retrograde approach was the primary strategy in 40.4% of lesions, with noteworthy indications such as long occlusion (35.7%), ostial involvement of the occlusion (21.3%), and presence of a lateral branch in the proximal cap (20.9%). The dissection and re-entry technique was the second most successful strategy (11.5%), followed by the antegrade approach (9.6%).

The rate for failure to cross the occlusion was 18.4%; failure advancing the guidewire through the collateral branch (64.2%) was the main cause, followed by difficulties in re-entry (19.7%) or failure advancing the microcatheter. The average technical success was 78.7%, and the procedural success was 76.6%.

Read also: Tricuspid Regurgitation: Natural Progression and Prognosis.

When the retrograde approach failed, technical success was achieved in 50.3% of cases using the antegrade approach. The incidence of major adverse events was 3.5%, with a clinically relevant coronary perforation rate of 5.8%. The rate for need for pericardiocentesis in those cases was 1.3%.

There were no significant differences in in-hospital adverse events among various techniques when they were successful (2.3% for retrograde, 3.5% for antegrade, and 3.4% for retrograde; P=0.38). Retrograde true lumen puncture was achieved in 31.8%, followed by reverse controlled antegrade and retrograde tracking (CART) (34.4%) and reverse CART with guide catheter extension (19.4%). The most frequently used collaterals were septal (62%), saphenous vein grafts (17.4%), or contralateral collaterals (15.7%), with no significant differences in adverse events based on the chosen collateral.

Conclusions

Lesion complexity and complication rates were significant in this cohort with adequate experience, and the procedural success rates were moderate (60.5%). However, retrograde true lumen crossing proved to be safer compared with dissection and re-entry techniques.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: The Retrograde Approach to Chronic Total Occlusion Percutaneous Coronary Interventions.

Reference: Allana, S, Kostantinis, S, Rempakos, A. et al. The Retrograde Approach to Chronic Total Occlusion Percutaneous Coronary Interventions: Technical Analysis and Procedural Outcomes. J Am Coll Cardiol Intv. 2023 Nov, 16 (22) 2748–2762. https://doi.org/10.1016/j.jcin.2023.08.031.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...